Compliance with dosing recommendations from common references in prescribing antibiotics for preterm neonates

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 1, 2010, Pages 51-58

  Cheng, Ching Lan ^a   Yang, Yea Huei Kao ^a   Lin, Swu Jane ^b   Lin, Chyi Her ^c   Lin, Yuh Jyh ^c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antibiotics; Compliance; Neonates; Preterm infants

Indexed keywords

AMIKACIN; AMPICILLIN; GENTAMICIN; METRONIDAZOLE; OXACILLIN; SULTAMICILLIN; VANCOMYCIN;

ARTICLE; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEWBORN INTENSIVE CARE; PATIENT COMPLIANCE; PREMATURITY; PRESCRIPTION; PRIORITY JOURNAL; REFERENCE VALUE; RETROSPECTIVE STUDY; TAIWAN; TERTIARY HEALTH CARE; UNIVERSITY;

ANTI-BACTERIAL AGENTS; DRUG PRESCRIPTIONS; FEMALE; GUIDELINE ADHERENCE; HOSPITALS, TEACHING; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INTENSIVE CARE UNITS, NEONATAL; MALE; REFERENCE BOOKS; REFERENCE STANDARDS; RETROSPECTIVE STUDIES; TAIWAN;

EID: 75749151666     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1858     Document Type: Article

References (31)

1. Ross LM, Wallace J, Paton JY. Medication errors in a paediatric teaching hospital in the UK: five years operational experience. Arch Dis Child 2000; 83: 492-497.
2. Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001; 285: 2114-2120.
3. Kaushal R, Barker KN, Bates DW. How can information technology improve patient safety and reduce medication errors in children's health care? Arch Pediatr Adolesc Med 2001; 155: 1002-1007.
4. Taketomo CK. Pediatric Dose Handbook: Including Neonatal Dosing, Drug Administration,& Extemporaneous Preparations (9th edn), Lexi-Comp & APhA: Ohio, 2002.
5. Young TE. Neofax (15th edn), Acorn Publishing, Inc.: North Carolina, 2002.
6. Batt DR. Neonatal Drug Formulary (5th edn), N.D.F: Los Angeles, 2002.
7. Gard JW, Starnes HM. Reducing antimicrobial dosing errors in a neonatal intensive care unit. Am J Health-Syst Pharm 1995; 52: 1508-1509.
8. Kenyon CF, Knoppert DC, Lee SK, et al. Amikacin pharmacokinetics and suggested dose modifications for the preterm infant. Antimicrob Agents Chemother 1990; 34: 265-268.
9. Cervantes-Munguía R, Trujillo-López JJ, Vásquez-Garibay E, et al. The amikacin on premature newborn: schema of treatment defined by gestational and postnatal age. Rev Biomed 2000; 11: 251-256.
10. van Wyk JT, van Wijk MA, Moorman PW, et al. Cross-sectional analysis of guidelines on cardiovascular disease risk factors: going to meet the inconsistencies. Med Decis Making 2006; 26: 57-62.
11. Jolley MR, Bess DI. Drug interaction inconsistency in drug information handbook. Am J Health-Syst Pharm 1998; 55: 2418-2419.
12. Koren G, Barzilay Z, Modan M. Errors in computing drug doses. Can Med Assoc J 1983; 129: 721-723.
13. Fenton TR. A new growth chart for preterm babies: Babson and Benda's chart updated with recent data and a new format. BMC Pediatr 2003; 3: 13-22.
14. Doumas HR, Jendrzejczak BT, Nemeth BM, et al. Relationship between nutrition, weight change, and fluid compartments in preterm infants during the first week of life. J Pediatr 1993; 122: 110-114.
15. Ehrenkranz RA, Younes N, Lemons JA, et al. Longitudinal growth of hospitalized very low birth weight infants. Pediatrics 1999; 104: 280-289.
16. Paap CM, Nahata MC. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokinet 1990; 19: 280-318.
17. Freeman CD, Nicolau DP, Belliveau PP, et al. Once-daily dosing of amioglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997; 39: 677-686.
18. Knoderer CA, Everett JA, Buss WE. Clinical issues surrounding oncedaily aminoglycoside dosing in children. Pharmacotherapy 2003; 23: 44-56.
19. Koren G. Therapeutic drug monitoring principles in the neonate. Clin Chem 1997; 43: 222-227.
20. Berger A, Kretzer V, Gludovatz P, et al. Evaluation of an amikacin loading dose for nosocomial infections in very low birthweight infants. Acta Paediatr 2004; 93: 356-360.
21. Rusconi F, Parini R, Cavanna G, et al. Monitoring of amikacin in the neonate. Ther Drug Monit 1983; 5: 179-183.
22. Gal P. Therapeutic drug monitoring in neonates: problems and issues. Drug Intell Clin Pharm 1998; 22: 317-323.
23. Howard JB, McCracken GH. Pharmacological evaluation of amikacin in neonates. Antimicrob Agents Chemother 1975; 8: 86-90.
24. Prober CG, Yeager AS, Arvin AM. The effect of chronologic age on the serum concentrations of amikacin in sick term and premature infants. J Pediatr 1981; 98: 636-640.
25. Vanpee M, Blennow M, Linne T, et al. Renal function in very low birth weight infants: normal maturity reached during early childhood. J Pediatr 1992; 121: 784-788.
26. Rybak MJ, Albrecht LM, Bolke SC, et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679-687.
27. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993; 32: 325-334.
28. Jager-Roman E, Doyle PE, Baird-Lambert J, et al. Pharmacokinetics and tissue distribution of metronidazole in the newborn infant. J Pediatr 1982; 100: 651-654.
29. Lentelink MB, de Vries TW, van Dijk KN. Accidental metronidazole overdose in a preterm newborn. Clin Pharmcokinet 1997; 32: 496-497.
30. Labia R, Morand A, Lelievre V, et al. Sulbactam: biochemical factors involved in its synergy with ampicillin. Rev Infect Dis 1986; 8: S496-S502.
31. Lamp KC, Freeman CD, Klutman NE, et al. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 1999; 36: 353-373.